Chris Lancaster
University of Houston(US)
Publications by Year
Research Areas
Clostridium difficile and Clostridium perfringens research, Microscopic Colitis, Gut microbiota and health, Nosocomial Infections in ICU, Antimicrobial Resistance in Staphylococcus
Most-Cited Works
- → Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection(2021)38 cited
- → Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial(2022)37 cited
- → Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection(2020)31 cited
- → PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255(2020)29 cited
- → A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects(2020)23 cited
- → Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains(2019)22 cited
- → Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing(2018)21 cited
- → Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile(2024)19 cited
- → In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile(2020)17 cited
- → In vitro activity of eravacycline against common ribotypes of Clostridioides difficile(2020)16 cited